查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726177

骨质疏鬆症药物市场规模、份额、趋势分析报告：按药物类别、类型、分销管道、地区和细分市场预测，2025 年至 2030 年

Osteoporosis Drugs Market Size, Share, & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

骨质疏鬆症治疗市场的成长与趋势

根据Grand View Research, Inc.的最新报告，全球骨质疏鬆症治疗市场预计到2030年将达到188亿美元，2025年至2030年期间的复合年增长率为3.5%。

不健康生活方式的激增导致骨质疏鬆症的加重和盛行率的增加，预计这将在预测期内推动骨质疏鬆症治疗市场的发展。

此外，专利到期的增加增加了临床使用成熟药物学名药的紧迫性，预计这将在预测期内推动非专利骨质疏鬆症治疗市场的发展。上述因素的结合将在未来几年创造巨大的潜在成长机会。

此外，在预测期内，加强提高患者和医生对骨质疏鬆症治疗的意识层级也有望增强骨质疏鬆症市场的成长潜力。例如，负责国家骨骼健康联盟和骨折联络服务（FLS）护理协调计划的医疗保健组织国家骨质疏鬆症基金会（NOF）致力于提高意识层级并为医疗保健专业人员提供培训。

骨质疏鬆症治疗市场报告重点

  • 2024年，品牌药物将占据产品领域的主导地位。这种主导份额归因于双磷酸盐、活化因数配体抑制剂的广泛应用，其在治疗骨质疏鬆症方面具有很高的疗效。
  • 由于未来几年专利将陆续到期，且新兴经济体的临床对平价药品的需求很高，预计学名药将以良好的复合年增长率增长。
  • 由于现有企业广泛参与品牌治疗的商业化，预计北美将在 2024 年占据全球骨质疏鬆症治疗市场的最大份额。
  • 由于政府采取积极倡议推广与骨质疏鬆症治疗相关的讯息，亚太地区预计将以指数级复合年增长率成长。
  • 为了获得竞争优势，主要参与企业正在采用永续性策略来推动骨质疏鬆症治疗的采用。例如，Actavis Inc.宣布收购Warner Chilcott PLC以扩大产品系列。

目录

第一章调查方法与范围

第二章执行摘要

3. 骨质疏鬆症治疗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

4. 骨质疏鬆症治疗市场：药物类业务分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年药品类别市场规模、预测及趋势分析
  • 品牌
  • 学名药

第五章骨质疏鬆症治疗市场：按类型分類的业务分析

  • 2024年和2030年的类型市场占有率
  • 类型细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2018-2030 年）
  • 双磷酸盐
  • 副甲状腺素治疗
  • 抑钙素
  • 选择性雌激素抑制剂调变器（SERM）
  • 活化因数配体抑制剂
  • 其他的

第六章骨质疏鬆症治疗市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 网路药局

第七章骨质疏鬆症治疗市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 2018-2030年各国情况
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • GSK plc
    • Radius Health, Inc.
    • UCB SA
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-1-68038-762-9

Osteoporosis Drugs Market Growth & Trends:

The global osteoporosis drugs market size is expected to reach USD 18.8 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights:

  • Branded drugs held the dominant share of the product segment in 2024. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
  • Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
  • In 2024, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
  • Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
  • The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Osteoporosis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Osteoporosis Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Generics
    • 4.5.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Osteoporosis Drugs Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Bisphosphonates
    • 5.4.1. Bisphosphonates Market, 2018 - 2030 (USD Million)
  • 5.5. Parathyroid Hormone Therapy
    • 5.5.1. Parathyroid Hormone Therapy Market, 2018 - 2030 (USD Million)
  • 5.6. Calcitonin
    • 5.6.1. Calcitonin Market, 2018 - 2030 (USD Million)
  • 5.7. Selective Estrogen Inhibitors Modulator (SERM)
    • 5.7.1. Selective Estrogen Inhibitors Modulator (SERM) Market, 2018 - 2030 (USD Million)
  • 5.8. Rank Ligand Inhibitors
    • 5.8.1. Rank Ligand Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.9. Other Products
    • 5.9.1. Other Products Market, 2018 - 2030 (USD Million)

Chapter 6. Osteoporosis Drugs Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Osteoporosis Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Eli Lilly and Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. GSK plc
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Radius Health, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. UCB S.A.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Teva Pharmaceutical Industries Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. F. Hoffmann-La Roche Ltd
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Osteoporosis Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4. Global Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5. Global Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 6. Global Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7. North America Osteoporosis Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8. North America Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9. North America Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 10. North America Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12. U.S. Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 13. U.S. Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14. Canada Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15. Canada Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 16. Canada Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18. Mexico Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 19. Mexico Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20. Europe Osteoporosis Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21. Europe Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22. Europe Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 23. Europe Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24. UK Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25. UK Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 26. UK Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27. Germany Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28. Germany Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 29. Germany Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30. France Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31. France Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 32. France Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33. Italy Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34. Italy Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 35. Italy Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36. Spain Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37. Spain Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 38. Spain Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39. Norway Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40. Norway Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 41. Norway Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43. Denmark Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 44. Denmark Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46. Sweden Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 47. Sweden Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Osteoporosis Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52. Japan Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53. Japan Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 54. Japan Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55. China Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56. China Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 57. China Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58. India Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59. India Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 60. India Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61. Australia Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62. Australia Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 63. Australia Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65. South Korea Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 66. South Korea Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 68. Thailand Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 69. Thailand Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America Osteoporosis Drugs Market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72. Latin America Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 73. Latin America Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75. Brazil Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 76. Brazil Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78. Argentina Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 79. Argentina Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Osteoporosis Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85. South Africa Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 86. South Africa Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90. UAE Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91. UAE Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 92. UAE Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Osteoporosis Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Osteoporosis Drugs Market, by Type, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Osteoporosis Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Osteoporosis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation drug class
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class, type and distribution channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Osteoporosis drugs market dynamics
  • Fig. 12 Osteoporosis drugs market: Porter's five forces analysis
  • Fig. 13 Osteoporosis drugs market: PESTEL analysis
  • Fig. 14 Osteoporosis drugs market: Drug class segment dashboard
  • Fig. 15 Osteoporosis drugs market: Drug class market share analysis, 2024 & 2030
  • Fig. 16 Branded market, 2018 - 2030 (USD Million)
  • Fig. 17 Generics market, 2018 - 2030 (USD Million)
  • Fig. 18 Osteoporosis drugs market: type segment dashboard
  • Fig. 19 Osteoporosis drugs market: type market share analysis, 2024 & 2030
  • Fig. 20 Bisphosphonates market, 2018 - 2030 (USD Million)
  • Fig. 21 Parathyroid hormone therapy market, 2018 - 2030 (USD Million)
  • Fig. 22 Calcitonin market, 2018 - 2030 (USD Million)
  • Fig. 23 Selective estrogen inhibitors modulator (SERM) market, 2018 - 2030 (USD Million)
  • Fig. 24 Rank ligand inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 25 Other products market, 2018 - 2030 (USD Million)
  • Fig. 26 Osteoporosis drugs market: distribution channel segment dashboard
  • Fig. 27 Osteoporosis drugs market: distribution channel market share analysis, 2024 & 2030
  • Fig. 28 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 31 Osteoporosis drugs market revenue, by region
  • Fig. 32 Regional marketplace: key takeaways
  • Fig. 33 Regional marketplace: key takeaways
  • Fig. 34 North America osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Country dynamics
  • Fig. 36 U.S. Osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia pacific osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait osteoporosis drugs market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework